Autopsy report · NCT04569461

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)

“Discontinuation of funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Duke University

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

pembrolizumab; Low dose prostate radiation; Radical Prostatectomy

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• A Study of APR-246 in Oesophageal Cancer
  “Funding ceased” (80% match in meaning)
• Evaluating the CAREchart@Home™ Program for Enhancing After-hours Cancer Care
  “Due to unforeseen circumstances, the funder decided to discontinue all funding.” (79% match in meaning)
• Evaluating the Effectiveness of Hybrid and Traditional Speech Therapy for /ɹ/ and /s/ Sound Production
  “Funding discontinued” (79% match in meaning)
• Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
  “Withdrawal of funding” (78% match in meaning)
• Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury
  “Funding Termination” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.